1. Home
  2. ACT vs TGTX Comparison

ACT vs TGTX Comparison

Compare ACT & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enact Holdings Inc.

ACT

Enact Holdings Inc.

N/A

Current Price

$49.19

Market Cap

6.6B

Sector

Finance

ML Signal

N/A

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$54.27

Market Cap

7.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACT
TGTX
Founded
1981
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6B
7.9B
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
ACT
TGTX
Price
$49.19
$54.27
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
$44.25
$49.80
AVG Volume (30 Days)
305.7K
2.2M
Earning Date
05-05-2026
05-04-2026
Dividend Yield
1.90%
N/A
EPS Growth
3.43
1746.67
EPS
2.42
0.17
Revenue
$1,235,827,000.00
$2,785,000.00
Revenue This Year
$4.06
$49.08
Revenue Next Year
$2.33
$26.69
P/E Ratio
$20.30
$297.41
Revenue Growth
2.83
N/A
52 Week Low
$34.64
$26.76
52 Week High
$50.56
$59.30

Technical Indicators

Market Signals
Indicator
ACT
TGTX
Relative Strength Index (RSI) 61.57 59.92
Support Level $41.97 $51.22
Resistance Level N/A $58.08
Average True Range (ATR) 0.88 2.10
MACD -0.08 0.39
Stochastic Oscillator 69.91 80.70

Price Performance

Historical Comparison
ACT
TGTX

About ACT Enact Holdings Inc.

Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The company operates in a single reportable segment namely Mortgage Insurance The principal mortgage insurance customers are originators of residential mortgage loans that determines the mortgage insurer or insurers to be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: